Prof Jennifer Doudna speaks to ecancer at the WIN 2019 Symposium in Paris about the use of genome editing using CRISPR-Cas9 to understand the genetic basis of cancer and to target the immune system.

She explains the basics of this technology and how this may be used in the context of cancer immunotherapy - such as to reprogram T-cells to recognise cancer cells more effectively.

Prof Doudna also discusses the challenges associated with this method, including its delivery into specific tissue types and ethical challenges.